CA2421229A1 - Vaccine against microbial pathogens - Google Patents

Vaccine against microbial pathogens Download PDF

Info

Publication number
CA2421229A1
CA2421229A1 CA002421229A CA2421229A CA2421229A1 CA 2421229 A1 CA2421229 A1 CA 2421229A1 CA 002421229 A CA002421229 A CA 002421229A CA 2421229 A CA2421229 A CA 2421229A CA 2421229 A1 CA2421229 A1 CA 2421229A1
Authority
CA
Canada
Prior art keywords
vaccine
composition
gene
heat shock
microbial pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421229A
Other languages
English (en)
French (fr)
Inventor
Camilo Anthony Leo Selwyn Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunobiology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2421229A1 publication Critical patent/CA2421229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002421229A 2000-09-04 2001-09-04 Vaccine against microbial pathogens Abandoned CA2421229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021757.0 2000-09-04
GBGB0021757.0A GB0021757D0 (en) 2000-09-04 2000-09-04 Vaccine against microbial pathogens
PCT/GB2001/003964 WO2002020045A2 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Publications (1)

Publication Number Publication Date
CA2421229A1 true CA2421229A1 (en) 2002-03-14

Family

ID=9898866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421229A Abandoned CA2421229A1 (en) 2000-09-04 2001-09-04 Vaccine against microbial pathogens

Country Status (15)

Country Link
US (1) US20050232946A1 (enExample)
EP (1) EP1315518B1 (enExample)
JP (1) JP2004508339A (enExample)
CN (1) CN1452495A (enExample)
AT (1) ATE450270T1 (enExample)
AU (1) AU2001284261A1 (enExample)
CA (1) CA2421229A1 (enExample)
DE (1) DE60140681D1 (enExample)
DK (1) DK1315518T3 (enExample)
ES (1) ES2337653T3 (enExample)
GB (1) GB0021757D0 (enExample)
IL (1) IL154727A0 (enExample)
PT (1) PT1315518E (enExample)
WO (1) WO2002020045A2 (enExample)
ZA (1) ZA200301759B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1791811B1 (en) * 2004-09-21 2009-12-23 Astellas Pharma Inc. Aminoalcohol derivatives
CA2662164A1 (en) 2006-09-01 2008-03-06 Stirling John Edwards Method of eliciting or inducing an immune response
WO2009021291A1 (en) * 2007-08-16 2009-02-19 The University Of Sydney Mycobacterium vaccine formulation
KR20100082825A (ko) 2007-10-12 2010-07-20 씨에스엘 리미티드 유행성 인플루엔자 바이러스에 대항하여 면역 반응을 유발하는 방법
GB0910591D0 (en) 2009-06-19 2009-07-29 Immunobiology Ltd Method for the purification of protein complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB201104897D0 (en) 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same
CA2833633A1 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256878B1 (en) * 1986-08-18 1993-04-14 Btg International Limited Vaccines
US5776724A (en) * 1988-10-24 1998-07-07 Yale University Chaperonin-mediated protein folding
JPH03204820A (ja) * 1989-10-12 1991-09-06 Nippon Saibai Suisan Kk エビ類の細菌性疾病予防ワクチン及びその製造法
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH08509873A (ja) * 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
JPH0748398A (ja) * 1993-08-03 1995-02-21 Nippon Oil Co Ltd 変性蛋白質の再生方法及び変性蛋白質再生剤
US6420127B1 (en) * 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
US6872542B1 (en) * 1993-11-18 2005-03-29 Siga Pharmaceuticals, Inc. Treatment or prophylaxis of diseases caused by pilus-forming bacteria
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
EA199800046A1 (ru) * 1995-06-07 1998-06-25 Байокем Вэксинс Инк. Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
ATE329031T1 (de) * 1995-11-30 2006-06-15 Agriculture Victoria Serv Pty Therapeutische zusammensetzungen zur behandlung von lawsonia intracellularis infektionen
EP0950061A4 (en) * 1996-09-20 2000-04-12 Univ New Mexico Heat shock protein complexes
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6331388B1 (en) * 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) * 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6500434B1 (en) * 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6576244B1 (en) * 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection
GB9818133D0 (en) * 1998-08-19 1998-10-14 Quadrant Holdings Cambridge Vaccine
JP2002537351A (ja) * 1999-02-22 2002-11-05 ユニバーシティ・オブ・ブリティッシュ・コロンビア コーロバクターリポ多糖免疫アジュバント
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
GB9919734D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines from infectious agents
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
CA2406472A1 (en) * 2000-04-17 2001-10-25 James E. Rothman Javelinization of protein antigens to heat shock proteins
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
US6932985B2 (en) * 2000-10-10 2005-08-23 Auburn University Azide method and composition for controlling deleterious organisms
WO2002059156A2 (en) * 2000-12-22 2002-08-01 Medimmune, Inc. Therapeutic compounds structurally-linked to bacterial polypeptides
US20030216315A1 (en) * 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
WO2003074003A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunogens for treatment of neoplastic and infectious disease
AU2003301296A1 (en) * 2002-05-02 2004-05-04 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines

Also Published As

Publication number Publication date
AU2001284261A1 (en) 2002-03-22
DK1315518T3 (da) 2010-04-19
ES2337653T3 (es) 2010-04-28
EP1315518A2 (en) 2003-06-04
ZA200301759B (en) 2004-06-22
CN1452495A (zh) 2003-10-29
ATE450270T1 (de) 2009-12-15
JP2004508339A (ja) 2004-03-18
WO2002020045A2 (en) 2002-03-14
DE60140681D1 (de) 2010-01-14
EP1315518B1 (en) 2009-12-02
IL154727A0 (en) 2003-10-31
US20050232946A1 (en) 2005-10-20
GB0021757D0 (en) 2000-10-18
PT1315518E (pt) 2010-03-05
WO2002020045A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
Cassataro et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection
Gupta et al. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis
Chambers et al. Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83
Singh Salmonella vaccines for animals and birds and their future perspective
Clausse et al. Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice
Hajam et al. Incorporation of membrane-anchored flagellin into Salmonella Gallinarum bacterial ghosts induces early immune responses and protection against fowl typhoid in young layer chickens
EP1315518B1 (en) Vaccine against microbial pathogens
EP1370284B1 (en) Bacteriophage-mediated immunisation
US20050175635A1 (en) Method and composition
EP1204422B1 (en) Stress-proteins from extra-cellular pathogens as vaccines against infectious agents
EP1212349A1 (en) Recombinant subunit vaccine
EP4061414A1 (en) A novel vaccine against heamophilus parasuis
AU2005204321B2 (en) Vaccines from Infectious Agents
Dow et al. Immunization with f-Met peptides induces immune reactivity against Mycobacterium tuberculosis
WANG et al. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin‐2 against Mycobacterium tuberculosis in BALB/c mice
CN1182871C (zh) 抗胞内病原体的疫苗
Silva et al. DNA encoding individual mycobacterial antigens protects mice against tuberculosis
Liu et al. Immunogenicity of recombinant BCGs expressing predicted antigenic epitopes of bovine viral diarrhea virus E2 gene
Kumar Vaccines Against Leishmaniasis
Helper Vaccination with the Recombinant
Kennedy The view on vaccination.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued